Gilead Sciences (GILD) Current Taxes (2009 - 2015)
Gilead Sciences (GILD) reported Current Taxes of $356.0 million for Q2 2015, up 265.87% on a YoY basis from $97.3 million in Q2 2014, and up 263.27% quarter-over-quarter from $98.0 million in Q1 2015.
Gilead Sciences (GILD) Current Taxes (2009 - 2015) Analysis & Trends
Gilead Sciences has reported Current Taxes for 7 years, with the latest figure at $356.0 million in Q2 2015.
- For the quarter ending Q2 2015, Current Taxes rose 265.87% year-over-year to $356.0 million; the trailing twelve-month figure through Jun 2015 stood at $356.0 million (up 265.87% YoY), and the FY2014 full-year result was $105.0 million, up 854.55% from the prior year.
- Current Taxes for Q2 2015 stood at $356.0 million, up from $98.0 million in the prior quarter.
- The five-year high for Current Taxes was $356.0 million in Q2 2015, with the low at $2.5 million in Q1 2011.
- Historically, Current Taxes has averaged $59.5 million across 5 years, with a median of $26.5 million in 2011.
- The largest YoY upside for Current Taxes was 2079.54% in 2011 against a maximum downside of 93.62% in 2011.
- Gilead Sciences' Current Taxes stood at $40.6 million in 2011, then tumbled by 66.97% to $13.4 million in 2012, then slipped by 17.93% to $11.0 million in 2013, then soared by 854.55% to $105.0 million in 2014, then jumped by 239.05% to $356.0 million in 2015.
- The last three Current Taxes figures came in at $356.0 million (Q2 2015), $98.0 million (Q1 2015), and $105.0 million (Q4 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -748.24 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 1.09 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 356.00 Mn |
| Mar 31, 2015 | 98.00 Mn |
| Dec 31, 2014 | 105.00 Mn |
| Sep 30, 2014 | 43.78 Mn |
| Jun 30, 2014 | 97.30 Mn |
| Mar 31, 2014 | 152.95 Mn |
| Dec 31, 2013 | 11.00 Mn |
| Sep 30, 2013 | 10.65 Mn |
| Jun 30, 2013 | 37.97 Mn |
| Mar 31, 2013 | 19.24 Mn |
| Dec 31, 2012 | 13.40 Mn |
| Sep 30, 2012 | 17.09 Mn |
| Jun 30, 2012 | 11.85 Mn |
| Mar 31, 2012 | 14.49 Mn |
| Dec 31, 2011 | 40.58 Mn |
| Sep 30, 2011 | 33.67 Mn |
| Jun 30, 2011 | 5.44 Mn |
| Mar 31, 2011 | 2.46 Mn |
| Dec 31, 2010 | 1.86 Mn |
| Sep 30, 2010 | 38.71 Mn |